Our goal is to develop a personalized cardiac digital twin tool that combines patient-specific electrical and structural information into a mathematical model: DIDIMO (Greek word for «twin») that will serve to:
- (A) evaluate in-silico tens of therapeutic strategies in a personalized way and select the optimal treatment for each patient.
- (B) accelerate pharmacological and medical device development by placing innovative technology in the hands of the industry to optimize clinical trials and obtain safer and more effective products.
DIDIMO project is constituted by an interdisciplinary team composed by: 2 Spanish medical devices start-ups, Adas3D Medical, SL and CORIFY CARE, SL; that will collaborate with the ITACA and CMT groups of Universitat Politècnica de Valencia (UPV), in charge of developing DIDIMO; and Hospital Clinic of Barcelona through IDIBAPS Institute, in charge of performing a clinical proof of concept.
The DIDIMO consortium will combine the imaging technology of ADAS 3D (i.e. late gadolinium enhancement -LGE- MRI quantification), the electrophysiological mapping technology of CORIFY CARE (i.e. Electrocardiographic Imaging) with the electrical, mechanical and fluid modelling experience of UPV to develop a workflow to produce cardiac digital twins and test therapies that will be validated at IDIBAPS.
The technological solution DIDIMO will increase the efficacy of treatments for cardiac arrhythmias, increasing the number of cured patients and reducing healthcare costs. In addition, it will serve to accelerate drug and medical device developments.
Grant PID2020-119364RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”